

## Myelofibrosis Treatment

Reference Number: RDF1666-23

Date of Response: 02/08/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

*I have a Freedom of Information query regarding the treatment for Myelofibrosis. Could you please answer the following questions:*

*Q1. Does your Trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?*

Answer: Yes.

*Q2. Please provide the total number of patients treated in the last 6 months for:*

- *Polycythaemia Vera (ICD10 code D45)*
- *Myelofibrosis (ICD10 code D47.4)*
- *Myelofibrosis (ICD10 code D47.4) patients aged 65 and older*

Answer: Please see table below.

	Total
Polycythaemia Vera	71
Myelofibrosis	16
Myelofibrosis (65+)	13

*Q3. How many patients were treated in the past 6 months (for any disease) with:*

- *Ruxolitinib*
- *Fedratinib*

Answer: Please see table below.

	Total
Ruxolitinib	20
Fedratinib	Nil

Q4. *Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:*

- *Polycythaemia Vera (ICD10 code D45)*
- *Myelofibrosis (ICD10 code D47.4)*

Answer: Please see table below.

	Total
Polycythaemia Vera	Nil
Myelofibrosis	11

Q5. *How many myelofibrosis (ICD10 code D47.4) patients has your Trust diagnosed in the past 3 years?*

Answer: 67.

a. *Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?*

Answer: ≤5. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

b. *Of these patients, how many were treated in the past 6 months with Interferon therapy?*

Answer: ≤5.

c. *Of these patients, how many have received no active treatment in the past 6 months?*

Answer: 32.

Q6. *Does your Trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.*

Answer: The Trust does not currently have any active trials for the treatment of myelofibrosis.